Cargando…
Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier
INTRODUCTION: Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early‐stage subjects do not worsen clinically during a clinical trial, and a neurodegenerative measure predictive of decline could pr...
Autores principales: | Matthews, Dawn C., Lukic, Ana S., Andrews, Randolph D., Wernick, Miles N., Strother, Stephen C., Schmidt, Mark E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270637/ https://www.ncbi.nlm.nih.gov/pubmed/35846158 http://dx.doi.org/10.1002/trc2.12325 |
Ejemplares similares
-
FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease
por: Matthews, Dawn C., et al.
Publicado: (2018) -
Dissociation of Down syndrome and Alzheimer's disease effects with imaging
por: Matthews, Dawn C., et al.
Publicado: (2016) -
Multivariate wavelet frames
por: Skopina, Maria, et al.
Publicado: (2016) -
Regional uptakes from early-frame amyloid PET and (18)F-FDG PET scans are comparable independent of disease state
por: Myoraku, Alison, et al.
Publicado: (2022) -
Boosting the diagnostic power of amyloid-β PET using a data-driven spatially informed classifier for decision support
por: Venkataraman, Ashwin V., et al.
Publicado: (2021)